Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak
Go back to Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak| Harmony Metals, Inc. Common (NASDAQ: HRMY) | Delayed: 34.16 +0.73 (2.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.43 | 52 Week High | $1.35 | |||
| Open | $33.67 | 52 Week Low | $0.10 | |||
| Day High | $34.31 | P/E | N/A | |||
| Day Low | $33.44 | EPS | $0.00 | |||
| Volume | 467,840 | |||||
